Form 4: Pelthos Director Einhorn Granted 12,000 RSUs

Pelthos Therapeutics director Andrew J. Einhorn received a grant of 12,000 Restricted Stock Units as compensation for his board service.

Summary

• Andrew J. Einhorn, a Director of Pelthos Therapeutics Inc. (PTHS), was granted 12,000 Restricted Stock Units (RSUs).
• The transaction date for this grant was December 23, 2025.
• The RSUs were granted as compensation for Mr. Einhorn's service as a member of the issuer's board of directors.
• The grant was made pursuant to the issuer's 2023 Equity Incentive Plan, which was amended and restated effective April 16, 2025.
• Each RSU represents a contingent right to receive one share of Pelthos Therapeutics Inc.'s Common Stock, par value $0.0001 per share.
• The 12,000 RSUs will vest on January 1, 2027.

Sentiment

Score: 7

Explanation: The grant of RSUs to a director is a positive step for aligning management and shareholder interests, reflecting standard corporate governance practices and incentivizing long-term commitment.

Positives

• The grant of Restricted Stock Units aligns the director's long-term interests with those of the shareholders, incentivizing sustained company performance.
• Equity compensation is a standard practice for attracting and retaining qualified board members.

Future Outlook

The 12,000 Restricted Stock Units granted to Director Andrew J. Einhorn are scheduled to vest on January 1, 2027, which will result in the potential issuance of 12,000 shares of common stock at that time.

Industry Context

Granting equity compensation, such as Restricted Stock Units, to non-employee directors is a standard practice across various industries, including biotechnology and pharmaceuticals. This method is widely used to align the interests of board members with the long-term value creation for shareholders and to attract experienced talent to the board.

Comparison to Industry Standards

• Many public companies, particularly in the biotech sector, utilize similar equity incentive plans to compensate non-executive directors. For instance, companies like Biogen or Gilead Sciences frequently grant RSUs or stock options to their board members as part of their compensation packages.
• The vesting schedule, with a single vesting date approximately one year after the grant, is consistent with common industry practices for director equity compensation, which often vest over one to three years to encourage long-term commitment.
• The grant of 12,000 RSUs is within typical ranges for director equity compensation in similar-sized companies, reflecting a standard approach to incentivizing board service.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential minor dilution upon the vesting and issuance of shares, but also improved alignment of the director's interests with long-term shareholder value and company performance.
• Director (Andrew J. Einhorn): Receives equity compensation, incentivizing continued commitment and contributions to the company's strategic direction and oversight.

Next Steps

• Vesting of 12,000 Restricted Stock Units on January 1, 2027.
• Potential issuance of 12,000 shares of common stock to Andrew J. Einhorn upon vesting.

Key Dates

Keywords

Pelthos Therapeutics, PTHS, Andrew J. Einhorn, Form 4, Restricted Stock Units, RSU, Director Compensation, Equity Incentive Plan, Insider Transaction